Discovery of a novel histone deacetylase 8 inhibitor by virtual screening

Medicinal Chemistry Research

Volumn 21, Issue 2, 2012, Pages 152-156

  Zhang, Lei ^a   Li, Minyong ^a   Feng, Jinhong ^a   Fang, Hao ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Docking; Histone deacetylase inhibitors; Pharmacophore modeling; Virtual screening

Indexed keywords

HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 8 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; COMPUTER MODEL; CRYSTAL STRUCTURE; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; IC 50; MOLECULAR DOCKING; PHARMACOPHORE;

EID: 84861917256     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-010-9519-7     Document Type: Article

References (24)

1. Bernstein BE, Tong JK, Schreiber SL (2000) Genomewide studies of histone deacetylase function in yeast. Proc Natl Acad Sci USA 97:13708-13713
2. De Ruijter AJM, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg ABP (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737-749 (Pubitemid 36399066)
3. Foglietti C, Filocamo G, Cundari E, De Rinaldis E, Lahm A, Cortese R, Steinkuhler C (2006) Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling. J Biol Chem 281:17968-17976 (Pubitemid 44035596)
4. Giandomenico V, Simonsson M, Gronroos E, Ericsson J (2003) Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol Cell Biol 23: 2587-2599 (Pubitemid 36351037)
5. Gregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338:17-31 (Pubitemid 38429783)
6. Gronroos E, Hellman U, Heldin CH, Ericsson J (2002) Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell 10:483-493 (Pubitemid 35284169)
7. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11:71-76 (Pubitemid 40215840)
8. Jin YH, Jeon EJ, Li QL, Lee YH, Choi JK, Kim WJ, Lee KY, Bae SC (2004) Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem 279:29409-29417 (Pubitemid 38915820)
9. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299 (Pubitemid 37361445)
10. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21:2672-2681 (Pubitemid 34619383)
11. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26 (Pubitemid 33653411)
12. Liu XH, Song HY, Zhang JX, Han BC, Wei XN, Ma XH, Cui WK, Chen YZ (2010) Identifying novel type ZBGs and nonhydroxamate HDAC inhibitors through a SVM-based virtual screening approach. Mol Inform 29:407-420
13. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194-202 (Pubitemid 33741894)
14. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51 (Pubitemid 43054973)
15. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F et al (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11:77-84 (Pubitemid 40215841)
16. Rarey M, Kramer B, Lengauer T, Klebe G (1996) A fast flexible docking method using an incremental construction algorithm. J Mol Biol 261:470-489 (Pubitemid 26335901)
17. Rarey M, Kramer B, Lengauer T (1997) Multiple automatic base selection: protein-ligand docking based on incremental construction without manual intervention. J Comput Aided Mol Des 11:369-384 (Pubitemid 127506743)
18. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95:3003-3007 (Pubitemid 28135844)
19. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E et al (2004) Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12:1325-1334 (Pubitemid 38900774)
20. Sun ZW, Hampsey M (1999) A general requirement for the Sin3-Rpd3 histone deacetylase complex in regulating silencing in Saccharomyces cerevisiae. Genetics 152:921-932 (Pubitemid 29330893)
21. Tang H, Wang XS, Huang XP, Roth BL, Butler KV, Kozikowski AP, Jung M, Tropsha A (2009) Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation. J Chem Inf Model 49:461-476
22. Thangapandian S, John S, Sakkiah S, Lee KW (2010) Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design. Eur J Med Chem 45: 4409-4417
23. Zhang YJ, Fang H, Jiao J, Xu WF (2008) The structure and function of histone deacetylases: the target for anti-cancer therapy. Curr Med Chem 15:2840-2849
24. Zhang YJ, Feng JH, Liu CX, Zhang L, Jiao J, Fang H, Su L, Zhang XP, Zhang J, Li MY et al (2010) Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors. Bioorg Med Chem 18:1761-1772